Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant by Freistaat Thüringen and co-funded by ESF Plus (European Social Fund).
Levodopa/Carbidopa: The Gold Standard Parkinson’s Treatment
Levodopa /Carbidopa is the most prescribed and effective treatment currently available for Parkinson's Disease.
Commercially available tablets of Levodopa/Carbidopa typically contain a uniform combination of 100mg of Levodopa and 25mg of Carbidopa. Carbidopa reduces the degradation of Levodopa in the bloodstream, enhancing its effectiveness.
Levodopa is an aromatic acid which alleviates the motor symptoms of PD by compensating for the decrease in endogenous dopamine. When paired with dopa-decarboxylase inhibitor Carbidopa, the half-life of Levodopa increases from 50 minutes to 90 minutes, preventing breakdown of the aromatic acid outside the central nervous system and preserving Levodopa for the brain.
LXM.5: New Generation Levodopa/Carbidopa
With the support of ESF Plus and the Free State of Thuringia, Laxxon is developing a New Generation Levodopa/Carbidopa, LXM.5, that releases the active pharmaceutical ingredients sequentially.
Laxxon’s LXM.5 Advanced Levodopa/Carbidopa solves crucial problems found with generic Levodopa/Carbidopa treatments:
LXM.5 eliminates the common “Freezing of Gait” effect through its sequential release of Levodopa and Carbidopa.
LXM.5 is designed to reduce daily doses while extending API efficacy for hours through the heterogeneous distribution of Carbidopa and Levodopa
As a result, Parkinson’s patients will sustain motoric freedom overnight and into the next day. This allows patients to reclaim personal autonomy by administering their own medication without caretaker support.
LXM.5 Formulation Structure
The LXM.5 Levodopa /Carbidopa tablet’s inner architecture is made up of Immediate Release (IR) Carbidopa (CD) and Extended Release (ER) Levodopa (LD), which is then coated in a delayed release polymer.
Generic Levodopa/Carbidopa vs. LXM.5
LXM.5 has several benefits over currently marketed Levodopa/Carbidopa products. Because of LXM.5's sequential release profile, the tablet first releases Carbidopa, increasing bioavailability of Levodopa and thus improving patient’s PD symptoms. Additionally, current Levodopa/Carbidopa formulations cannot be achieved without administering multiple tablets separately.
To stay up to date on Laxxon's latest developments, follow us on LinkedIn.
#LXM5 #NewGenerationLevodopaCarbidopa #LaxxonMedical #InnovateWithUs #ESFPlus #Thuringen #Parkinsons